Abstract Library

#2818 Is It That Rare?

Introduction: Carcinoid heart disease (CHD) is a rare and unique manifestation, It present in 50% of CS

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Babli S

Authors: Babli S, Alzahrani W, Aldawish M,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease,

#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)

Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davies P

Authors: Davies P, Quaglia E, McSweeney A, Caplin M, Thirlwell C,

Keywords: Nurse, Non-Medical Prescribing, SACTs, neuroendocrine, chemotherapy, everolimus, sunitinib,

#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Zandee W, Franssen G, Hofland J, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumors, Palliative surgery, Prognosis,

#2063 Interim Analyses LANREL07484: Response to Treatment and Self-Reported Satisfaction in Symtoms in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa

Introduction: An ongoing South African observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Geldenhuys D

Authors: Geldenhuys D, Jacobs C, Rapoport B, Fourie S, Szpak W,

Keywords: gastroenteropancreatic neuroendocrine tumors, Flushing, Diarrhoea, Lanreotide Autogel,

#2062 Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa

Introduction: LANRELO7484 is an ongoing, observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) in South Africa (SA).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Geldenhuys D

Authors: Geldenhuys D, Jacobs C, Rapoport B, Fourie S, Szpak W,

Keywords: Gastroenteropancreatic Neuroendocrine Tumors, Quality of Life,